Business Wire

 Panasonic and KOSÉ Set to Commence Verification Test for Personalized Proposals Utilizing Snow Beauty Mirror

6.12.2019 05:37:00 EET | Business Wire | Press release

Share

Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Snow Beauty Mirror (Displays the results of skin analysis covering five categories) (Photo: Business Wire)

People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum is personalized proposals which utilize digital technologies and data to introduce individuals to the optimal products and services.

Maison KOSÉ is a new type of concept store, a place where people will be able to come and experience these personalized proposals firsthand using Snow Beauty Mirror. Visitors will also be able to try out Customized Sheets (provisional name), which adopts the Make-up Sheet technology currently under development at Panasonic.

Functions of Snow Beauty Mirror and content of verification test

1. Skin analysis

All customers need to do is sit in front of the mirror. The system then analyzes the customer’s skin profile and displays numerical data instantly on the mirror. Contactless sensors embedded in the mirror detect the condition of both the skin’s surface and below the surface. With a degree of precision on par with medical devices, the system detects not only spots, wrinkles, smile lines, pores and skin tone, but also hidden spots otherwise invisible to the naked eye. Then, based on digital counselling and analysis results, the system recommends the optimal package for each individual customer from among KOSÉ’s products and services spanning multiple brands*1. This function utilizes facial recognition and image processing technologies used in digital cameras, et al.

2. Ideal face image system

Combining genetic algorithms, developed as a joint venture between KOSÉ and Meiji University, with Panasonic’s image processing technologies has enabled the creation of a system which makes it possible to visualize a person’s “ideal face” from facial image data—that is, how the customer would really like to appear. Snow Beauty Mirror’s high-precision skin analysis function detects the customer’s skin conditions in terms of pores, spots and wrinkles, as well as the skin’s tones and brightness, and adjusts the parameters of this data to create around 500,000 facial image patterns. The customer selects their preferred facial image from among randomly displayed facial images, generating their ideal face in a short time. The system can visualize the differences between the customer’s ideal face and current appearance, while providing tips on the perfect foundation tone, texture and application techniques to help them get closer to their ideal face.

3. Customized Sheets which apply Make-up Sheet technology

Currently under development at Panasonic, Make-up Sheets are ultra-thin*2 cosmetic sheets printed with tones that perfectly match the customer’s skin. They combine skin analysis data from Snow Beauty Mirror, and the company’s proprietary printing technology. Customers simply need to stick the sheets over areas of concern on their cheeks or temples.

In this verification test, Panasonic will combine its Make-up Sheet technology, proprietary skin tone analysis technology, and printing technology with KOSÉ’s extensive knowledge of cosmetic development. The aim is to create Customized Sheets (provisional name) that achieve a natural color match and an ideal fit with the customer’s skin.


Panasonic will continue to fuse its cutting-edge technologies with KOSÉ’s development capabilities in cosmetics to expand the scope of Snow Beauty Mirror, pursuing possibilities that go beyond the field of beauty treatment. In this way, the company will meet the diverse needs of its customers and better contribute to society through improved QOL.

Notes:
*1. KOSÉ Group’s skin care brands, excluding ALBION
*2. Thickness of 100 nanometers (one nanometer = one billionth of a meter)

About Maison KOSÉ

A fun concept store stocking and linking all KOSÉ brands*3, providing customers with an early chance to try a range of new software and hardware relating to cosmetics and beauty treatment. The store facilitates new forms of communication which fuse digital and experiential approaches, exploring new possibilities for the next generation of cosmetic experiences and working to connect customers digitally to the store. It also serves as a place of communication with customers, functioning as a seat of learning where information and experiences can be quickly fed back into the company.

*3 Excluding some products

About Panasonic

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2019/12/en191206-2/en191206-2.html

Related Links

[Video] Make-up Sheet / Technology & Innovation of Panasonic
https://channel.panasonic.com/contents/25818/

[Video] Solving skin concerns with innovation using the “Make-up Sheet” [Panasonic]
https://channel.panasonic.com/contents/25819/

Brand Story | Panasonic
https://www.panasonic.com/global/corporate/brand/story.html

Panasonic R&D Overview | Panasonic
https://www.panasonic.com/global/corporate/technology-design/r-and-d.html

Breakthrough Technology | Panasonic
https://www.panasonic.com/global/corporate/technology-design/technology.html

KOSÉ Corporation
https://www.kose.co.jp/global/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye